结核病预防性治疗研究进展

doi:10.3969/j.issn.1000-6621.2014.01.013

摘要/Abstract

摘要： 有效地诊断和治疗潜伏结核感染是预防和控制结核病流行的重要措施。对目前已发表的关于结核病预防性治疗的文献进行回顾，总结了多种预防性治疗的方案，对帮助结核病防治医务工作者选择合适的治疗方案具有参考价值。

Abstract: The effective diagnosis and treatment of latent tuberculosis infection is one of the most important measures for TB prevention and control. The author reviewed the current published literature on tuberculosis preventive therapy and summarized the treatment regimens. This would be of great value for the TB health workers to select the appropriate treatment regimen for patients.

Key words: Tuberculosis/prevention and control, Clinical protocols

刘二勇，成诗明，赖钰基，王冬梅，李涛，王黎明，王倪，徐晓玉，周林. 结核病预防性治疗研究进展[J]. 中国防痨杂志, 2014, 36(1): 59-63. doi: 10.3969/j.issn.1000-6621.2014.01.013

LIU Er-yong, CHENG Shi-ming, LAI Yu-ji, WANG Dong-mei, LI Tao, WANG Li-ming, WANG Ni, XU Xiao-yu, ZHOU Lin. Progress in TB preventive therapy[J]. Chinese Journal of Antituberculosis, 2014, 36(1): 59-63. doi: 10.3969/j.issn.1000-6621.2014.01.013

参考文献

［1］Corbett EL，Watt CJ,Maher D, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med, 2003,163(9): 1009-1021.
［2］［No authors listed］.Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med, 2000,161(4 Pt 2): S221-247.
［3］刘二勇，周林，成诗明.结核分枝杆菌潜伏性感染及预防性治疗研究进展的系统评价.中国防痨杂志，２０１３,３５（４）：231-238.
［4］Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc, 1970,26: 28-106.
［5］Ferebee SH, Mount FW. Chemotherapy of tuberculosis, progress and promise. Public Health Rep, 1957, 72(5): 412-420.
［6］Ferebee SH, Mount FW, Palmer CE. Tuberculosis prophylaxis trials in preview. Public Health Rep, 1957, 72(8): 703-704.
［7］Ferebee S, Mount FW, Anastasiades A. Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report. Am Rev Tuberc, 1957, 76(6): 942-963.
［8］Comstock GW, Ferebee SH, Hammes LM, A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis, 1967, 95(6): 935-943.
［9］Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis, 1962, 85: 490-510.
［10］Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology, 2010, 15(4): 603-622.
［11］Mount FW， Ferebee SH.The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis, 1962, 85: 821-827.
［12］Ferebee SH,Mount FW,Murray FJ, et al. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis, 1963, 88:161-175.
［13］Grzybowski S, Ashley MJ,mckinnon NE,et al. In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Can Med Assoc J, 1969, 101(9): 81-86.
［14］Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J, 1976, 114(7): 607-611.
［15］Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA, 1986, 255(12):1579-1583.
［16］［No authors listed］.Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982, 60(4): 555-564.
［17］［No authors listed］.Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000, 49(RR-6): 1-51.
［18］Long R. The Canadian Lung Associsation/Canadian Thoracic Society and tuberculosis prevention and control. Can Respir J, 2007, 14(7):427-431.
［19］Menzies D, Jahdali H Al,Otaibi B Al. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res, 2011, 133(3):257-266.
［20］Comstock GW,Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis, 1979, 119(5):827-830.
［21］Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis, 1999, 3(10): 847-850.
［22］Selwyn PA,Hartel D,Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med, 1989, 320(9): 545-550.
［23］Akolo C,Adetifl I,Shepperd S,et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010,20(1): CD000171.
［24］Cain KP,McCarthy KD,Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med, 2010, 362(8):707-716.
［25］World Health Organization.Policy statement on preventive therapy against tuberculosis in people living with HIV. Geneva: World Health Organization Global Tuberculosis Programme, Joint United Nations Programme on HIV/AIDS, 1998.
［26］World Health Organization.Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings. Geneva:World Health Organization,2011.
［27］Martinson NA,Barnes GL,Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med, 2011, 365(1): 11-20.
［28］Balcells ME, Thomas SL,godfrey-faussett P,et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis, 2006, 12(5): 744-751.
［29］Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis, 1978, 117(6):991-1001.
［30］Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associa-ted with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA, 1999, 281(11): 1014-1018.
［31］LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med, 2003, 168(4): 443-447.
［32］Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis, 1989, 140(5):1189-1193.
［33］Gao XF,Wang L,Lin GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis, 2006, 10(10):1080-1090.
［34］Gordin F,Chaisson RE,Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA, 2000, 283(11):1445-1450.
［35］Halsey NA,Coberly JS,Desormeaux J, et al., Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet, 1998, 351(9105):786-792.
［36］Ijaz K,Jereb JA,Lambert LA, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis, 2006, 42(3):346-355.
［37］Centers for Disease Control and Prevention,American Thoracic society.Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep, 2003, 52(31):735-739.
［38］Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis, 2010, 14(11): 1374-1381.
［39］Schechter M, Zaidenverq T,falco G,et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med, 2006, 173(8):922-926.
［40］Sterling TR, Villarino ME,Borisov AS,et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166.
［41］Centers for Disease Control and Prevention.Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep, 2011, 60(48):1650-1653.
［42］Dorman SE，Johnson JL,Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med, 2009, 180(3): 273-280.

[1]	赵本南, 刘大凤, 刘亚玲, 杨铭, 兰丽娟, 杜清. 含丙硫异烟胺和对氨基水杨酸方案治疗耐多药结核病患者致甲状腺功能减退症的临床分析[J]. 中国防痨杂志, 2020, 42(5): 465-471.
[2]	《耐药脊柱结核临床诊疗专家共识》编写组. 耐药脊柱结核临床诊疗专家共识[J]. 中国防痨杂志, 2019, 41(4): 377-382.
[3]	范琳,熊坤龙,肖和平. 建国70年来结核病化学治疗的历史进程要览[J]. 中国防痨杂志, 2019, 41(11): 1145-1148.
[4]	孙雯雯,楼海,孙勤. 含利福布汀方案治疗缓慢生长型非结核分枝杆菌肺病的短期疗效分析[J]. 中国防痨杂志, 2018, 40(9): 948-953.
[5]	金龙,胡卫华,卢水华. 糖尿病对耐多药肺结核的影响与对策[J]. 中国防痨杂志, 2018, 40(9): 999-1002.
[6]	王茂军,马丙乾,郝俊玲,付志华,董淑敏,曹艳竹. 不同方案治疗单耐异烟肼或利福平肺结核患者的预后分析[J]. 中国防痨杂志, 2018, 40(3): 286-291.
[7]	方勇，肖和平. 潜伏性结核感染的诊治进展[J]. 中国防痨杂志, 2016, 38(2): 144-147.
[8]	杜鹃，田丹，陈国玺，姚芳，陈俊，兰星，袁保东. 初治涂阳肺结核患者采用含氟喹诺酮类药物治疗方案的疗效分析[J]. 中国防痨杂志, 2016, 38(11): 968-972.
[9]	肖和平. 立法管理结核病传染源刻不容缓[J]. 中国防痨杂志, 2015, 37(9): 921-922.
[10]	刘一典编译沙巍审校. 使用含替加环素方案挽救性治疗52例脓肿分枝杆菌和龟分枝杆菌感染的临床经验 [J]. 中国防痨杂志, 2015, 37(9): 991-991.
[11]	李涛，成诗明，杜昕. 全国结核病防治工作模式与患者发现和治疗管理水平分析[J]. 中国防痨杂志, 2015, 37(1): 30-34.
[12]	艾静文，阮巧玲，张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展[J]. 中国防痨杂志, 2015, 37(1): 80-85.
[13]	姜世闻，刘小秋. 我国流动人口结核病防治工作的进展与展望[J]. 中国防痨杂志, 2014, 36(9): 798-801.
[14]	周林，刘二勇. 国内外Mtb与HIV双重感染防治进展与展望[J]. 中国防痨杂志, 2014, 36(9): 802-805.
[15]	钟球，尹建军，高翠南，张建辉，周琳. 我国结核病防治科普工作的回顾与展望[J]. 中国防痨杂志, 2014, 36(9): 806-809.